INTEGRA®

LIMIT UNCERTAINTY

Q1 2022 EARNINGS PRESENTATION

APRIL 27, 2022

Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” “target,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, and income tax expense (benefit) related to non-GAAP adjustments and other items, capital return plans and expectations and plans with respect to strategic initiatives and product development. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the magnitude and duration of the COVID-19 pandemic and its effects on our employees, customers, patients, suppliers and distributors, including the economic impacts of the various recommendations, orders and protocols issued by governmental agencies and other regulatory bodies; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate acquired businesses; the Company’s ability to achieve sales growth in a timely fashion and execute on its channel reorganization in its Tissue Technologies segment; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Device Regulation; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2021 and information contained in subsequent filings with the Securities and Exchange Commission.

These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Measures

In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) intangible asset amortization expense; and (v) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment.

Reconciliations of GAAP revenues to organic revenues, GAAP adjusted net income to adjusted EBITDA and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended March 31, 2022 and 2021, and the free cash flow and adjusted free cash flow conversion for the quarters ended March 31, 2022 and 2021, appear in the financial tables in this presentation.

The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this presentation filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.

Executing On Our Strategy

Q1 Financial Performance

Total revenue $376.6 million – above high end of guidance

- Procedure volumes steadily improved in March
- Supply met accelerated demand
- 5.6% organic growth[1]

Adj. earnings per share $0.74 – above high end of guidance

- 7% increase
- Adj. gross margin +40bps vs. prior year

FY 2022 Guidance

Organic Growth	Increased to 3.8% to 5.2%
Revenue	$1,580 - $1,600 million
Adjusted EPS	$3.27 to $3.35

Business Highlights

Broad surgical procedure recovery across portfolio

- ≥ 5% organic growth in CSS and TT

Focused actions to protect margins in inflationary environment

- Selective price increases
- Operational yields and procurement focus

Prioritizing investments for growth

- Resource investments: Operations, Commercial, R&D
- Launched NeuraGen®3D and continued global rollout of CereLink® in Canada, Australia and several indirect markets

Completed $125 million share repurchase

Capturing procedure growth recovery while protecting margins

[1]Q1 2022 excludes $3.1M related to discontinued and divested products, $2.7M of acquired ACell revenues and ($4.6M) in foreign exchange; Q1 2021 excludes $4.7M related to discontinued and divested products
Note: Organic growth, adj. earnings per share, and adj. gross margin are non-GAAP financial measures.

First Quarter Financial Highlights



Stronger revenue recovery and adjusted EPS outperformance

[1]Q1 2022 excludes $3.1M related to discontinued and divested products, $2.7M of acquired ACell revenues and ($4.6M) in foreign exchange; Q1 2021 excludes $4.7M related to discontinued and divested products
Note: Organic growth, adj. earnings per share, adj. EBITDA margin and adj. gross margin are non-GAAP financial measures.

Codman Specialty Surgical Q1 Revenue

Revenues	Q1'22	Q1'21	Growth
Reported	$247.3M	$241.2M	2.5%
Organic[1]	$248.4M	$236.6M	5.0%

Q1 2022 Growth and Performance Drivers[2]		
Neurosurgery	**Instruments**	**International**
5.8%	2.1%	Mid-Single Digits

- Neurosurgery – High single-digit growth in CSF Management; Low double-digit growth in Neuro Monitoring driven by new CereLink; Low single-digit growth in Dural Access and Repair
- Instruments – Growth in line with long-term expectations; Prior year benefited from pent-up demand
- International – Low double-digit growth in China and Japan; Contributions from recent CereLink launch

Q1 2022 Revenue Composition



Broad demand recovery in Neurosurgery

[1]Q1 2022 excludes $3.1M related to discontinued and divested products and ($4.2M) in foreign exchange; Q1 2021 excludes $4.7M related to discontinued and divested products;
[2]Percentages based on organic revenue; Commentary represents organic performance; Comparisons are to prior year

Tissue Technologies Q1 Revenue

Revenues	Q1'22	Q1'21	Growth
Reported	$129.3M	$118.8M	8.8%
Organic[1]	$127.1M	$118.8M	6.9%

Q1 2022 Growth and Performance Drivers[2]		
Wound Reconstruction	**Private Label**	**International**
4.1%	15.2%	Mid-Single Digits

- Wound Reconstruction – Growth led by Integra Skin and SurgiMend®; ACell revenue in line with expectations
- Private Label – Increase driven by higher customer demand and favorable order timing
- International – Growth led by SurgiMend and Integra Skin in Europe and Private Label in Canada

Q1 2022 Revenue Composition



Strong procedure recovery in Tissue Technology

[1]Q1 2022 organic growth excludes $2.7M of acquired ACell revenues and ($0.4M) in foreign exchange
[2]Percentages based on organic revenue; Commentary represents organic performance; Comparisons are to prior year

Q1 2022 Financial Results ($M except per share data)



- Revenue: $377M, above high end of guidance provided in February, driven by procedure recovery and order timing
- Adj. Gross Margin: In line with expectations, up 40 basis points vs. prior year
- Adj. EBITDA Margin: In line with expectations, reflecting higher planned investments
- Adj. EPS: 7% growth vs. prior year driven by higher revenue

Strong revenue performance and resilient adj. gross margin

Note: Organic growth, adj. gross margin, adj. EBITDA margin and adj. EPS are non-GAAP financial measures.

Balance Sheet and Cash Flow Performance

Summary Balance Sheet ($M)	12/31/21	3/31/22
Cash and Cash Equivalents	$513	$407
Total Debt	$1,563	$1,562
Net Debt	$1,050	$1,155
Available Credit	$1,267	$1,256
Total Available Liquidity	$1,780	$1,663
Consolidated Total Leverage Ratio	2.3x	2.5x

Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%)



Completed $125M ASR while maintaining total leverage ratio at low end of 2.5-3.5X targeted range

Note: Adj. FCF conversion is a non-GAAP financial measure.

Q2 2022 and FY 2022 Outlook

Q2 Reported Revenue Guidance Bridge ($M)

2022 Reported Revenue Guidance Bridge ($M)



Q2 2022

- Revenue: $392M-$400M
  - Reported Growth +0.5% to +2.5%
  - Organic Growth +2.8% to +4.8%
- Adj. EPS $0.78 - $0.82

FY 2022

- Reaffirmed Revenue: $1,580M-$1,600M
  - Reaffirmed Reported Growth +2.5% to +3.5%
  - Raised Organic Growth +3.8% to +5.2%
- Reaffirmed Adj. EPS $3.27 - $3.35

Raising organic revenue guidance given strong start to the year

Note: Organic growth and adj. EPS are non-GAAP financial measures.

Integra Growth Catalysts

Near- to Mid-Term Growth Catalysts

- **Post-COVID procedure growth recovery**
- **International opportunities led by Japan and China**
- **Global Cerelink Launch**
- **ACell contribution / commercial expansion**
- **Aurora® – MIS clinical evaluations underway**
- **PriMatrix® DFU data publication / efforts to expand reimbursement**
- **SurgiMend – Breast PMA**
- **NeuraGen 3D commercial roll-out**

First Quarter Performance & Progress

- ✓ Broad-based organic growth despite COVID-related disruptions in beginning of quarter
  - ≥ 5% organic growth in both segments
  - Double-digit organic growth in Japan and China
- ✓ CereLink launch expanded to Canada, Australia, and several indirect markets
- ✓ ACell poised for second half growth
- ✓ Advancing Aurora clinical evaluations and MIRROR registry
- ✓ NeuraGen 3D launch end of March

Executing on NPI and International opportunities while strengthening organizational capabilities

Note: Organic growth is a non-GAAP financial measure.

INTEGRA®
LIMIT UNCERTAINTY

Appendix

Non-GAAP Reconciliations

First Quarter 2022 Financial Results

% of Revenues	Q1 2022	Q1 2021	Change
Total Revenues	$376.6	$360.1	4.6%
Gross Margin	62.1%	59.5%	+260BPS
Adj. Gross Margin[(1)]	67.7%	67.3%	+40BPS
Net Income	$32.9	$45.4	(27.5%)
Adj. Net Income[(1)]	$62.0	$59.0	5.1%
Adj. EBITDA Margin[(1)]	24.8%	25.0%	-20BPS
Diluted Shares Out (M)	84.3	85.3	(1.2%)
Earnings per Share	$ 0.39	$ 0.53	(26.4%)
Adj. Earnings per Share[(1)]	$ 0.74	$ 0.69	7.2%

(1) These are non-GAAP financial measures. Please see the Appendix of this presentation for a reconciliation to the nearest GAAP measure.

Note: Numbers may not add due to rounding

First Quarter 2022 Organic Growth Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021
Neurosurgery	$194.7	$189.3
Instruments	$52.6	$52.0
Total Codman Specialty Surgical	**$247.3**	**$241.2**
Wound Reconstruction and Care	$94.6	$88.7
Private Label	$34.7	$30.1
Total Tissue Technologies	**$129.3**	**$118.8**
Total Reported Revenues	**$376.6**	**$360.1**
Revenues from divested products[(1)]	(0.8)	(0.2)
Revenues from discontinued products[(1)]	(2.3)	(4.5)
Revenues ex divested/ discontinued products	**373.5**	**355.4**
Impact of changes in currency exchange	4.6	-
Revenues from acquisitions[(2)]	(2.7)	-
Total Organic Revenues	**$375.4**	**$355.4**
Organic Revenue Growth	*5.6%*	

(1) Organic revenue has been adjusted for 2022 and 2021 to account for divestitures and discontinued products
(2) Revenue from acquisitions includes ACell

First Quarter 2022 Adjusted EBITDA Margin Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021
GAAP Net Income	**$32.9**	**$45.4**
Depreciation	9.6	9.4
Intangible asset amortization	20.1	22.5
Other (income), net	(2.1)	(3.3)
Interest expense, net	10.3	11.2
Income tax expense/(benefit)	6.4	21.9
Acquisition, divestiture and integration-related charges[(1)]	0.6	(27.0)
Structural optimization charges	6.3	3.9
EU Medical Device Regulation	9.5	5.7
Total of non-GAAP adjustments:	60.6	44.5
Adjusted EBITDA	**$93.5**	**$89.9**
Total Revenues	376.6	360.1
Adjusted EBITDA Margin	**24.8%**	**25.0%**

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.

First Quarter 2022 Adjusted EPS Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021
GAAP Net Income	**$32.9**	**$45.4**
Acquisition, divestiture and integration-related charges[(1)]	0.6	(27.0)
Structural optimization charges	6.3	3.9
EU Medical Device Regulation	9.5	5.7
Intangible asset amortization expense	20.1	22.5
Estimated income tax impact from adjustments and other items	(7.4)	8.4
Total of non-GAAP adjustments:	29.1	13.6
Adjusted Net Income	**$62.0**	**$59.0**
Adjusted Diluted Net Income per Share	**$0.74**	**$0.69**
Weighted average common shares outstanding for diluted net income from continuing operations per share	84.3	85.3

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses. The company completed the sales of its Extremity Orthopedics business and recognized a gain of $42.9 million for the three months ended March 31, 2021.

First Quarter 2022 and 2021 (TTM) Adjusted Free Cash Flow Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021	TTM 2022	TTM 2021
Net Cash from Operating Activities	$44.3	$69.1	$287.7	$252.1
Purchases of Property and Equipment	($9.3)	($6.7)	($50.7)	($29.0)
Free Cash Flow	**$35.0**	**$62.4**	**$237.0**	**$223.1**
Adjusted Net Income	$62.0	$59.0	$274.6	$226.3
Adjusted Free Cash Flow Conversion	**56.5%**	**105.7%**	**86.3%**	**98.6%**

First Quarter 2022 Gross Margin Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021
Reported Gross Profit	**$234.1**	**$214.2**
Structural optimization charges	2.9	1.8
Acquisition, divestiture and integration-related charges	0.9	8.0
EU Medical Device Regulation	0.7	0.3
Intangible asset amortization expense	16.2	18.0
Adjusted Gross Profit	**$254.8**	**$242.4**
Total Revenues	$376.6	$360.1
Adjusted Gross Margin	**67.7%**	**67.3%**

First Quarter 2022 Adjusted SG&A Reconciliation

Note: Numbers may not add due to rounding

(In millions)	Q1 2022	Q1 2021
Reported SG&A	**$159.9**	**$156.6**
Structural optimization charges	3.3	1.6
Acquisition, divestiture and integration-related charges	2.1	7.8
EU Medical Device Regulation	3.5	2.1
Adjusted SG&A	**$151.0**	**$145.1**
Total Revenues	376.6	360.1
Adjusted SG&A (% of Revenues)	**40.1%**	**40.3%**